Co-Authors
This is a "connection" page, showing publications co-authored by Namrata Setia and Blase Polite.
Connection Strength
0.462
-
ASO Visual Abstract: Survival Outcomes in Early-Onset Appendiceal Adenocarcinoma (EOAA). Ann Surg Oncol. 2026 Sep; 33(9):8565-8566.
Score: 0.062
-
Survival Outcomes in Early Onset Appendiceal Adenocarcinoma (EOAA). Ann Surg Oncol. 2026 Sep; 33(9):8546-8554.
Score: 0.061
-
ASO Visual Abstract: Association of Activating GNAS Mutations and Outcomes with Chemotherapy in Metastatic Appendiceal Adenocarcinoma. Ann Surg Oncol. 2026 Apr; 33(4):3477-3478.
Score: 0.060
-
Association of Activating GNAS Mutations and Outcomes with Chemotherapy in Metastatic Appendiceal Adenocarcinoma. Ann Surg Oncol. 2026 Apr; 33(4):3453-3461.
Score: 0.060
-
MEN1/DAXX/ATRX mutations enhance progression-free survival in gastroenteropancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy. Endocr Relat Cancer. 2024 11 01; 31(11).
Score: 0.054
-
Single center outcomes from parenchymal-sparing resections and microwave ablations for neuroendocrine tumor liver metastases. Am J Surg. 2024 03; 229:17-23.
Score: 0.051
-
Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease. Cancer Discov. 2021 02; 11(2):308-325.
Score: 0.042
-
Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Netw Open. 2020 02 05; 3(2):e1921290.
Score: 0.039
-
Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. Cancer Discov. 2018 01; 8(1):37-48.
Score: 0.033